The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil

International Journal of Impotence Research

Volumn 13, Issue 5, 2001, Pages 282-290

  Saenz De Tejada, I ^a,b   Angulo, J ^a,b   Cuevas, P ^b   Fernandez A ^b   Moncada, I ^a   Allona, A ^a,b   Lledo E ^a   Korschen H G ^c   Niewohner U ^d   Haning, H ^d   Pages, E ^d   Bischoff, E ^d  

^a Fundación para la Investigación Y El Desarrollo en Andrología   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

^d BAYER AG   (Germany)

Author keywords

Cyclic GMP; Impotence; In vitro; In vivo; Nitric oxide; PDE5; Penile erection; Phosphodiesterase inhibitors; Smooth muscle relaxation

Indexed keywords

CYCLIC GMP; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE RELAXATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ACETYLCHOLINE; ANIMALS; CATTLE; CYCLIC GMP; ELECTRIC STIMULATION; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; ISOENZYMES; MALE; MUSCLE RELAXATION; MUSCLE, SMOOTH; NERVOUS SYSTEM PHYSIOLOGY; NITROPRUSSIDE; PENILE ERECTION; PENIS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; RABBITS; SULFONES; TRIAZINES; VASODILATOR AGENTS;

EID: 0035157613     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900726     Document Type: Article

References (34)

1. Trabecular smooth muscle modulates the capacitor function of the penis. Studies on a rabbit model
2. About arterial risk factors and impotence
3. Impotence
4. Erectile dysfunction due to atherosclerotic vascular disease: The development of an animal model
5. A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle
6. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission
7. Endothelium-derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone
8. Nitric oxide: A physiologic mediator of penile erection
9. G-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit
10. Role of nitric oxide in the physiology of erection
11. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A
12. Multiple cyclic nucleotide phosphodiesterases
13. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction
14. Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle
15. Expression of different phosphodiesterase genes in human cavernous smooth muscle
16. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
17. Phosphodiesterase activity in human cavernous tissue and the effect of various selective inhibitors
18. Nitric oxide is a potent relaxant of human and rabbit corpus cavernosum
19. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes
20. The role of cyclic adenosine monophosphate, cyclic guanosine monophosphate, endothelium and nonadrenergic, noncholinergic neurotransmission in canine penile erection
21. Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile function in the anesthetized dog
22. A conscious rabbit model is able to demonstrate the efficacy of vardenafil and sildenafil on penile erection
23. Oral sildenafil in the treatment of erectile dysfunction
24. Nitric oxide is involved in the inhibitory neurotransmission and endothelium-dependent relaxations of human small penile arteries
25. Neuroleptics induce penile erection in the rabbit
26. The role of phosphodiesterase inhibitors in impotence
27. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence
28. Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle
29. Safety tolerability and pharmacokinetics of multiple dose treatment with the new PDE5-inhibitors BAY 39-9456
30. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: A Rigiscan™ and pharmacokinetic study
31. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose
32. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial
33. Vardenafil, a new highly selective PDE5 inhibitor, improves erectile function irrespective of the base-line severity and etiology of ED or age of patient
34. The oral efficacy of vardenafil hydrochloride for inducing penile erections in a conscious rabbit model